澤璟製藥(688266.SH):傑克替尼臨牀試驗已經有約40家知名醫院參與了研究
格隆匯6月1日丨有投資者向澤璟製藥(688266.SH)提問:公司傑克替尼片未來的銷售策略?
澤璟製藥回覆:對傑克替尼未來的銷售,公司已經開始佈局,傑克替尼臨牀試驗已經有約40家知名醫院參與了研究,該領域內主要專家對傑克替尼的療效和安全性都非常瞭解和認可,為傑克替尼的未來學術推廣奠定了良好的基礎;公司現有的商業團隊中的部分核心人員對血液病領域的產品推廣也比較熟悉,公司將在現有團隊核心骨幹架構的基礎上,新增招聘擅長血液病領域的市場、醫學和銷售推廣的優秀人才,進行傑克替尼治療骨髓纖維化的市場推廣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.